It is imperative for current research to systematically assess the safety and clinical efficacy of various bile acid receptor modulators through standardized clinical trials, with particular emphasis on the pivotal regulatory role of S1PR2 antagonists in the progression of MASLD-HCC [149]. This evidence concerns the gene S1PR2 and metabolic dysfunction-associated steatotic liver disease.